Vision Zero Cancer are proud to be a part of Community 365 – European Cancer Organisation

Yesterday Ebba Hallersjö Hult met Mike Morrissey, Chief Executive, European Cancer Organisation & President, European Society of Association Executives, at the EU Beating Cancer Plan and the EU Cancer Mission conference and continued our dialogue on how Vision Zero Cancer can contribute to the Focused Topic Network of the European Cancer Organisation.

 More about Community 365

Vision Zero Cancer now member in Lung Cancer Policy Network

The Lung Cancer Policy Network is a global alliance of almost 50 world-renowned experts in lung cancer and cancer screening, with the goal of making lung cancer a policy priority worldwide. The Network’s website has now launched, and we are pleased to say that Ebba Hallersjö Hult from Vision Zero Cancer is a member.

There is compelling evidence that implementing targeted screening programmes can transform lung cancer from a fatal to a treatable disease, and dramatically improve quality of life for people with lung cancer. The initial focus of the Network is to promote the adoption of screening to increase early detection and diagnosis of lung cancer.
Members of the Network include clinicians, researchers, patient organisations and advocates, and industry experts. All members share their knowledge and expertise, which feeds into an evidence base to encourage policymakers to make lung cancer a health policy priority worldwide. The Network will soon launch its inaugural report, outlining key lessons learnt from the implementation of lung cancer screening around the world, as well as an online map tracking the progress of lung cancer screening globally.

Visit the Network’s website for more information:

Sweden launches testbed for clinical trials in cancer care

Vision Zero Cancer and Genomic Medicine Sweden (GMS) join forces with SciLifeLab, public sector authorities, regions, healthcare, academia, industry and patient associations to create an innovation milieu that facilitates the introduction of more precise prevention and treatment in cancer care.

Through the call Innovation milieus within Precision Health 2021, The Swedish Innovation Agency, Vinnova, has chosen to invest in 11 innovation milieus in precision health that will pave the way for more prevention, precision, and equity in healthcare and contribute to strengthening Sweden as a life science nation.

– For cancer patients, this is a piece of the puzzle that enables the development of new innovations so that more people can live longer and better. This initiative consolidates Vision Zero Cancer as a national point of contact for system innovation and strengthens our ambition to spread  the Vision Zero globally says Ebba Hallersjö Hult, co-founder and head of Vision Zero Cancer and Test Bed Sweden.

Ebba Hallersjö Hult. Photo: Micke Lundström.

– GMS is very pleased to participate in this broad consortium that together can move the positions for national clinical studies in cancer in Sweden. At GMS, we are already working on a national, structured implementation of genomics-based precision medicine and we look forward to working together furthering more clinical studies, says Anders Edsjö, Vice Chairman of GMS management team, Section Head and Senior Molecular Pathologist at Clinical Genetics and Pathology, Region Skåne.

Anders Edsjö. Photo: Nooreldin Zendehrokh.

The research institute SIR at the Stockholm School of Economics is the coordinator for Vision Zero Cancer and for the new innovation milieu “Test Bed Sweden for Clinical Trials and Implementation of Precision Health in Cancer Care”, which has been granted funding for five years by Vinnova and which will be part of the national strategic innovation program Swelife.

The patient perspective is central to the initiative

– The Network against Cancer looks forward to the joint work within the testbed with a focus on co-creation with patients and relatives. We see great opportunities to push for a faster roll-out of clinical studies and the implementation of precision medicine, says Margareta Haag, Chair of the Network against Cancer.

Margareta Haag. Photo: private.

Comprised in the Life Science strategy, the government has a stated ambition that Sweden should be a pioneer for the introduction of precision medicine in healthcare. Predictions suggest that precision medicine is likely to grow primarily in cancer care over the next decade. In 10 years, between 300 and 400 new immunotherapies, targeted drugs and tumour agnostic drugs could be approved.

– Conducting clinical studies within healthcare is a prerequisite for patients in Sweden to be able to take part of the fantastic opportunities brought by precision medicine. The initiative Vinnova has now decided to finance will advance the positions for how we conduct clinical studies, which in turn means increased stimulation and prerequisites for more pharmaceutical companies to place their studies in Sweden and thereby contribute to the development of precision medicine, says Frida Lundmark, expert policy at Lif – the research pharmaceutical companies.

Frida Lundmark. Photo: Lif.

Wide range of actors behind the initiative

Test Bed Sweden is an add-on and further development of the Vinnova-funded innovation milieu Vision Zero Cancer established in 2019 with the long-term vision that no one should have to die of cancer. Behind the Test Bed initiative and application are 16 different actors (see box below). The range of actors is something seen as a key to succeed.

– By developing and implementing precision medicine through diagnostics and treatment in clinical routine, there is a good chance to reach the Vision Zero. Giving patients faster access to effective and nationally equitable precision health in the field of cancer is crucial, says Hans Hägglund, Sweden’s national cancer coordinator and co-founder of Vision Zero Cancer and Test Bed Sweden.

Hans Hägglund. Photo: Micke Lundström.

– Sweden needs an innovation milieu to stimulate and facilitate national clinical studies within precision medicine for patients with cancer. We have gathered a number of important players who need to be involved to make this possible. The testbed has national and international reach to initiatives and groups of actors that can contribute and collaborate in this endeavor, concludes Richard Rosenquist Brandell, Chairman of GMS management team, Professor and Senior Physician in Clinical Genetics at Karolinska Institutet and Karolinska University Hospital.

Richard Rosenquist Brandell. Photo: Rick Guidotti.


Ebba Hallersjö Hult, tel: 072-711 44 91 [email protected]

Behind the initiative and application are the following actors: Vision Zero Cancer, Genomic Medicine Sweden (GMS), Regional Cancer Centres (RCC), The Medical Products Agency, The Dental and Pharmaceutical Benefits Agency (TLV), SciLifeLab, the consortium behind the clinical trial Megalit coordinated by Uppsala University Hospital in Region Uppsala, Stockholm School of Economics, Halmstad University, the Swedish Institute for Health Economics (IHE),  the Network against Cancer, Lung Cancer Association, Lif – the research pharmaceutical companies, Swedish Medtech and Ascro.

This is Vision Zero Cancer

Vision Zero Cancer challenges the prevailing ecosystem and connects new ones. We are going to turn cancer from a deadly into a curable or chronic disease.

Who we are
Follow link